Left Menu
Development News Edition

Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ("Coherus" Nasdaq:CHRS), under which Coherus will exclusively market and distribute Bioeq's biosimilar candidate to Lucentis® (ranibizumab) in the United States (U.S.)

Bioeq will retain responsibility for filing of the Biologics License Application (BLA) with the U.S. Food and Drug Administration in Q4 2019 and for subsequent product supply. Coherus plans to launch the product in 2021.

Commenting on the agreement, Hannes Teissl, Board Member at Bioeq, said, "We are proud of having secured Coherus as our partner of choice for the U.S. This agreement is an important milestone in bringing a more affordable, highly effective treatment option for retinopathies, including age-related macular degeneration, to U.S. patients."

According to the terms of the agreement, Bioeq will receive upfront, regulatory and launch milestone payments as well as shared profits.

Commenting on future plans, Nicola Mikulcik, Board Member at Bioeq, said, "Starting in 2020, Bioeq will also be in a position to offer rights for its biosimilar ranibizumab to marketing and distribution partners outside the U.S."

Editor's notes

Lucentis® is a registered trademark of Genentech, Inc. It is a biopharmaceutical product containing the monoclonal antibody ranibizumab, approved for eye conditions including neovascular ('wet') age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, and diabetic retinopathy. In the U.S., annual sales of Lucentis® are around USD 1.8b.1

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.

Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.


Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the European Union. For additional information, please visit www.coherus.com.

1. Reported US sales of CHF 1,798m equivalent to USD 1,816m (Fx 0,99). Roche, Quarterly Report Q3 2019. https://www.roche.com/investors.htm. Last accessed 4 November 2019.

For more information, please contact:

Edward Oliver
Ruder Finn UK



These innovators are making humanitarian response more efficient

These alarming trends prompt a call for the world to not only address the ongoing crisis but also to adopt innovative approaches to fulfill the growing humanitarian needs in such emergencies. ...

Hyderabad Encounter: A sentiment analysis of public mood on day of encounter

Sentiment analysis of twitter users revealed that they showered salutes on Hyderabad police for eliminating alleged gang rapists of the veterinary doctor but only a few believe in cops version of successive events leading to encounter....

Hyderabad Encounter: Time to review modern judiciary and restore people’s confidence

Its probably for the first time in the history of independent India, the parliamentarians, chief ministers and ministers in the Union and State governments are openly supporting an encounter. This indicates the people from top to bottom hav...

What happens to your outstanding loans if the bank falls?

... ...


Latest News

CAB: People defy curfew in Guwahati, Army conducts flag march

The people defied curfew in Guwahati on Thursday morning to protest against the Citizenship Amendment Bill as the situation remained tense throughout Assam, with the Army conducting flag march in the city. Guwahati, the epicentre of anti-CA...

Snooker star O'Sullivan refuses to shake hands over germ fears

London, Dec 12 AFP Snooker great Ronnie OSullivan added another chapter to his colourful career by refusing to shake hands with his opponent and the referee before a match at the Scottish Open on health grounds. Traditionally, players shake...

UPDATE 1-Police report arson attacks, vandalism overnight in Hong Kong

Hong Kong police said they arrested three people in connection with arson and vandalism in Kowloon late Wednesday. In a news release on Thursday morning, the police said three people - a 15-year-old girl, a 16-year-old boy and a 29-year-old...

Atletico, Atalanta reach last 16 as Bayern cruise past Spurs

Paris, Dec 12 AFP Atletico Madrid claimed the final spot in the Champions League last 16 with a 2-0 win over Lokomotiv Moscow, after Atalanta completed an impressive comeback in Group C to qualify. Bayern Munich sealed consecutive victories...

Give Feedback